Clinical practice China guidelines for male breast cancer (2023 edition)

Title: Clinical practice China guidelines for male breast cancer (2023 edition)
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: breast surgeon
Evidence classification method: Grading of Recommendations Assessment, Development and Evaluation
Development unit: 中华医学会外科学分会乳腺外科学组
Registration time: 2023-01-10
Registration number: PREPARE-2023CN024
Purpose of the guideline: Male breast cancer (MBC) is a rare malignancy, accounting for less than 1% of new breast cancers reported in the literature, and a multicenter study organized by the Chinese Society for Surgery reported that male breast cancer accounts for approximately 0.31% of the overall breast cancer population in China. In view of its low incidence, there are few randomized controlled studies on MBC, mainly retrospective studies with small samples, and the current principles of diagnosis and treatment of MBC are mostly extrapolated from studies related to female breast cancer, but there are obvious differences in the biological characteristics of MBC and female breast cancer, so in order to improve the standardization and scientificity of the diagnosis and treatment process of MBC in China, this guideline is based on a review of the domestic and international literature, with reference to In order to improve the standardization and scientificity of MBC diagnosis and treatment in China, this guideline is based on a review of the domestic and international literature and a quality of evidence evaluation of clinical issues related to MBC diagnosis and treatment with reference to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) standard, and the accessibility of clinical practice in Chinese breast surgery. The study was conducted to evaluate the quality of evidence on clinical issues related to the diagnosis and treatment of MBC.